EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Liposome-based diagnostic and therapeutic applications for pancreatic cancer

Faisal Raza, Lauren Evans, Mahzad Motallebi, Hajra Zafar, Miguel Pereira-Silva, Kalsoom Saleem, Diana Peixoto, Abbas Rahdar, Esmaeel Sharifi, Francisco Veiga, Clare Hoskins, Ana Cláudia Paiva-Santos

Acta Biomaterialia · 2023-02 · 157 · 1-23

DOI: 10.1016/j.actbio.2022.12.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2023-02. Verfasst von Faisal Raza und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address: faisalraza@sjtu.edu.cn. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pancreatic Neoplasms. Die Arbeit wurde bisher 83-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fundação para a Ciência e a Tecnologia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic cancer is one of the harshest and most challenging cancers to treat, often labeled as incurable. Chemotherapy continues to be the most popular treatment yet yields a very poor prognosis. The main barriers such as inefficient drug penetration and drug resistance, have led to the development of drug carrier systems. The benefits, ease of fabrication and modification of liposomes render them as ideal future drug delivery systems. This review delves into the versatility of liposomes to achieve various mechanisms of treatment for pancreatic cancer. Not only are there benefits of loading chemotherapy drugs and targeting agents onto liposomes, as well as mRNA combined therapy, but liposomes have also been exploited for immunotherapy and can be programmed to respond to photothermal therapy. Multifunctional liposomal formulations have demonstrated significant pre-clinical success. Functionalising drug-encapsulated liposomes has resulted in triggered drug release, specific targeting, and remodeling of the tumor environment. Suppressing tumor progression has been achieved, due to their ability to more efficiently and precisely deliver chemotherapy. Currently, no multifunctional surface-modified liposomes are clinically approved for pancreatic cancer thus we aim to shed light on the trials and tribulations and progress so far, with the hope for liposomal therapy in the future and improved patient outcomes. STATEMENT OF SIGNIFICANCE: Considering that conventional treatments for pancreatic cancer are highly associated with sub-optimal performance and systemic toxicity, the development of novel therapeutic strategies holds outmost relevance for pancreatic cancer management. Liposomes are being increasingly considered as promising nanocarriers for providing not only an early diagnosis but also effective, highly specific, and safer treatment, improving overall patient outcome. This manuscript is the first in the last 10 years that revises the advances in the application of liposome-based formulations in bioimaging, chemotherapy, phototherapy, immunotherapy, combination therapies, and emergent therapies for pancreatic cancer management. Prospective insights are provided regarding several advantages resulting from the use of liposome technology in precision strategies, fostering new ideas for next-generation diagnosis and targeted therapies of pancreatic cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPancreatic NeoplasmsHumansLiposomesDrug Delivery SystemsDrug Carriers

Stichwörter der Autor:innen

CancerControlled releaseDrug deliveryIntratumorLiposomesNanocarrierStroma remodeling

Substanzen

LiposomesAntineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China. Electronic address: faisalraza@sjtu.edu.cn.
  • Pure and Applied Chemistry, University of Strathclyde, 99 George Street, Glasgow, G1 1RD, UK.
  • Immunology Board for Transplantation And Cell-based Therapeutics (Immuno_TACT), Universal Scientific Education and Research Network (USERN), Tehran 7616911319, Iran; Nanomedicine Research Association (NRA), Universal Sc…
  • School of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China.
  • Department of Pharmaceutical Technology, Faculty of Pharmacy of the University of Coimbra, University of Coimbra, Azinhaga Sta. Comba, 3000-548 Coimbra, Portugal; LAQV, REQUIMTE, Department of Pharmaceutical Technology,…
  • Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 45320, Pakistan.

Förderung

  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Raza, F., Evans, L., Motallebi, M., Zafar, H., Pereira-Silva, M., Saleem, K., Peixoto, D., Rahdar, A., Sharifi, E., Veiga, F., Hoskins, C., & Paiva-Santos, A. C. (2023). Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomaterialia, 157, 1-23. https://doi.org/10.1016/j.actbio.2022.12.013

Vancouver

Raza F, Evans L, Motallebi M, Zafar H, Pereira-Silva M, Saleem K, et al. Liposome-based diagnostic and therapeutic applications for pancreatic cancer. Acta Biomaterialia. 2023;157:1-23. doi:10.1016/j.actbio.2022.12.013

BibTeX
@article{Raza2023,
  author = {Raza, Faisal and Evans, Lauren and Motallebi, Mahzad and Zafar, Hajra and Pereira-Silva, Miguel and Saleem, Kalsoom and Peixoto, Diana and Rahdar, Abbas and Sharifi, Esmaeel and Veiga, Francisco and Hoskins, Clare and Paiva-Santos, Ana Cláudia},
  title = {Liposome-based diagnostic and therapeutic applications for pancreatic cancer},
  journal = {Acta Biomaterialia},
  year = {2023},
  volume = {157},
  pages = {1--23},
  doi = {10.1016/j.actbio.2022.12.013}
}
Kostenlos starten →